Posted On: 11/14/2016 10:15:22 AM
Post# of 23065
$GALT Posted On: 11/05 /2016 9:33:17 PM
Avatar
Posted By: fitzkarz
$GALT 0.61 0.10 +19.61 867,120
52 Week High 9/22/2016 | 3.05
52 Week Low 11/3/2016 | 0.49
Shares Outstanding 29.28M
Float 26.3M
Company Background
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
http://www.galectintherapeutics.com
Read More: http://investorshangout.com/post/view?id=4157...z4PzqLOGBT
Avatar
Posted By: fitzkarz
$GALT 0.61 0.10 +19.61 867,120
52 Week High 9/22/2016 | 3.05
52 Week Low 11/3/2016 | 0.49
Shares Outstanding 29.28M
Float 26.3M
Company Background
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
http://www.galectintherapeutics.com
Read More: http://investorshangout.com/post/view?id=4157...z4PzqLOGBT
(1)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
